Menu

Close

Sign InSign Out

Materials

Co-pay Cards & Patient Savings Offers

Request Samples

Hospital Products

Vaccines, Biologics & ​​​​​​​Small-molecule Medicines

Pfizer Oncology Together

Pfizer RxPathways

Events

Materials

Videos

Menu

Close

Efficacy

Phase III Study Primary Endpoints

Success in ISGA: Clear or ​​​​​​​almost clear

Study Design

Phase III Study Secondary Endpoints

ISGA clear or almost clear

Time to ISGA success

Phase III Study: Other Endpoints

Pruritus

Quality of life assessments

Infant Study: Exploratory efficacy Endpoints

ISGA clear or almost clear

%BSA, EASI & POEM

Safety Data

Phase III Study Adverse Reactions*

Pivotal trial & 48-week extension study
Adverse Reactions

Open-Label Safety Extension Study*

Open-Label Safety Extension Study Rescue ​​​​​​​Therapy Endpoint

Study design

Infant Safety Study**

Adverse Reactions

Study design and Demographics

Savings & Support

Events

Materials

Videos

Copay Cards

Cost and Coverage

  • Prescribing Information
  • Patient Information
  • Patient Site
  • Order Copay Savings Cards

    Select the number of Savings Cards required:

    Each offer has a unique identification number, so please make sure to distribute one to each patient.

    * Eligibility required. Individual savings limited to $970 per tube or $3,880 in maximum total savings per calendar year. Only for use with commercial insurance. If you are enrolled in a state or federally funded prescription insurance program, you may not use the savings card. Terms and Conditions apply

    Please confirm the following eligibility requirements:

    • I confirm that I am not licensed to practice medicine in the state of Vermont.*
    • I confirm that I am not an Advanced Practice Registered Nurse ("APRN") engaged in an independent practice in the state of Connecticut.*

    Offer must be accompanied with a valid prescription.
    Each offer must be printed directly from this website. Do not photocopy.

    * Indicates a required field

    Select how to receive your Savings Cards:

  • Where should we send the Savings Cards:

    * Indicates a required field

    Submit

    TERMS AND CONDITIONS


    You may be eligible for the EUCRISA Copay Savings Program if you currently use private or commercial health insurance to cover a portion of your medication costs for EUCRISA.

    TERMS AND CONDITIONS

    By using the EUCRISA Copay Savings Card, you acknowledge that you currently meet the eligibility criteria and will comply with the terms and conditions described below:

    • Eligibility Criteria:

    • You must have commercial insurance. Offer is not valid for cash-paying patients.
    • By using this copay card at participating pharmacies, eligible patients with commercial prescription drug insurance coverage for EUCRISA may pay as little as $10 per tube. Eligible patients with commercial prescription drug insurance coverage that does not cover EUCRISA may pay as little as $100 per tube. Individual savings are limited to $970 per tube. Individual patient savings are limited to $3,880 in maximum total savings per calendar year.
    • This copay card is not valid when the entire cost of your prescription drug is eligible to be reimbursed by your commercial insurance plan or any other health or pharmacy benefit program.
    • You must deduct the value of this copay card from any reimbursement request submitted to your commercial insurance plan, either directly by you or on your behalf.
    • You are responsible for reporting use of the copay card to any commercial insurer, health plan, or other third party that pays for or reimburses any part of the prescription filled using the copay card, as may be required. You should not use the copay card if your insurer or health plan prohibits use of manufacturer copay cards.
    • This copay card is not valid where prohibited by law.
    • Copay card cannot be combined with any other savings, free trial, or similar offer for the specified prescription.
    • Copay card will be accepted only at participating pharmacies.
    • This copay card is not health insurance.
    • Offer good only in the U.S. and Puerto Rico.
    • Copay card is limited to 1 per person during this offering period and is not transferable.
    • A copay card may not be redeemed more than once per 30 days per patient.
    • No other purchase is necessary.
    • Data related to your redemption of the copay card may be collected, analyzed, and shared with Pfizer, for market research and other purposes related to assessing Pfizer’s programs. Data shared with Pfizer will be aggregated and de-identified; it will be combined with data related to other copay card redemptions and will not identify you.
    • Pfizer reserves the right to rescind, revoke, or amend this offer at any time without notice.
    • Offer expires 3/31/2022.

    For questions or additional support, call 1-877-548-1739, write to Pfizer Inc., at PO Box 29387, Mission, KS 66201, or visit the EUCRISA website at www.eucrisa.com.

    Savings & Support Program

    A savings and support program for your patients to help them with their access to EUCRISA

    See resources

    Cost and Coverage

    Favorable access on many plans nationwide and is available at the lowest branded copay for many commercial and Medicare patients.

    View eligibility

    Contraindications

    EUCRISA is contraindicated in patients with known hypersensitivity to crisaborole or any component of the formulation.

    Warnings and Precautions

    Hypersensitivity reactions, including contact urticaria, have occurred in patients treated with EUCRISA and should be suspected in the event of severe pruritus, swelling, and erythema at the application site or at a distant site. Discontinue EUCRISA immediately and initiate appropriate therapy if signs and symptoms of hypersensitivity occur.

    Adverse Reactions

    The most common treatment-related adverse reaction occurring in clinical trials was application site pain, such as burning or stinging.

    Please see Full Prescribing Information and Patient Information

    EUCRISA is indicated for topical treatment of mild-to-moderate atopic dermatitis in adult and pediatric patients 3 months of age and older.

    INDICATION

    EUCRISA (crisaborole) is indicated for topical treatment of mild‑to‑moderate atopic dermatitis in adult and pediatric patients 3 months of age and older.

    EUCRISA is for topical use only and is not for ophthalmic, oral, or intravaginal use. For more information, please view the full prescribing information here.

    Please see full Prescribing Information.

    OK. We'll need you to sign in before we can determine if you are aligned with a sales  representative. 

    If you select 'Yes', you will be required to enter your username and password in the sign-in form  that will appear over this window.  

    Would you like to sign in now?